Immutep Limited (IMMP)
NASDAQ: IMMP · IEX Real-Time Price · USD
2.650
+0.050 (1.92%)
At close: Apr 26, 2024, 4:00 PM
2.570
-0.080 (-3.02%)
After-hours: Apr 26, 2024, 6:48 PM EDT

Immutep Revenue

Immutep had revenue of $4.58M in the twelve months ending December 31, 2023. In the fiscal year ending June 30, 2023, Immutep had annual revenue of $3.59M, a decrease of -23.58%.

Revenue (ttm)
$4.58M
Revenue Growth
-23.58%
P/S Ratio
76.20
Revenue / Employee
$111,628
Employees
41
Market Cap
348.77M USD

Revenue Chart

* The company reports in AUD currency but revenue data is shown in USD.

History

Fiscal Year End Revenue Change Growth
Jun 30, 20233.59M-1.11M-23.58%
Jun 30, 20224.69M1.71M57.30%
Jun 30, 20212.98M-8.40M-73.78%
Jun 30, 202011.38M6.11M115.75%
Jun 30, 20195.27M-172.67K-3.17%
Jun 30, 20185.45M2.20M67.77%
Jun 30, 20173.25M1.74M114.92%
Jun 30, 20161.51M-102.31K-6.34%
Jun 30, 20151.61M-1.35M-45.47%
Jun 30, 20142.96M-704.67K-19.24%
Jun 30, 20133.66M-632.41K-14.72%
Jun 30, 20124.30M3.15M275.71%
Jun 30, 20111.14M699.68K157.75%
Jun 30, 2010443.55K420.00K1,783.04%
Jun 30, 200923.56K--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Amarin Corporation 306.91M
Health Catalyst 295.94M
Revance Therapeutics 234.04M
Zynex 184.32M
ADC Therapeutics 69.56M
Mersana Therapeutics 36.86M
Precigen 6.23M
Sera Prognostics 306.00K
Revenue Rankings